Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 51407-817

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 51407-817). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-817-60lb (DULOXETINE 20MG DR CAPS)

Label for Duloxetine Delayed-Release Capsules USP 20 mg by Golden State Medical Supply, Inc. The label shows 60 capsules per container with an NDC of 51407-817-60. It states each capsule contains 22.4 mg duloxetine hydrochloride equivalent to 20 mg duloxetine, with storage and dispensing information. Includes a GSMS logo and a barcode.*

FDA Label Image

51407-818-30lb (DULOXETINE 30MG DR CAPS)

Label for Duloxetine Delayed-Release Capsules, USP, 30 mg strength, containing 30 capsules. The label specifies each capsule contains 33.7 mg duloxetine hydrochloride equivalent to 30 mg duloxetine. It is marked Rx Only and distributed by GSMS Incorporated. Includes storage instructions and a barcode.*

FDA Label Image

51407-819-30lb (DULOXETINE 60MG DR CAPS)

Label for Duloxetine Delayed-Release Capsules USP, 60 mg, by Golden State Medical Supply, Inc. The label states each capsule contains 67.3 mg duloxetine hydrochloride equivalent to 60 mg duloxetine. The package contains 30 capsules and is marked Rx only. Additional storage and dispensing instructions are included, along with NDC 51407-819-30 and a QR code.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure diagram of duloxetine hydrochloride, showing aromatic rings, a sulfur-containing heterocycle, and the molecular arrangement typical for this active ingredient.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time (days) between placebo and duloxetine delayed-release capsules. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The graph indicates fewer relapses in the duloxetine group compared to placebo over a 200-day period.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier survival curve graph illustrating the proportion of patients with relapse over time in days. The graph compares relapse rates between patients treated with Duloxetine delayed-release capsules and those receiving placebo, showing the proportion with relapse on the y-axis and time from randomization to relapse (days) on the x-axis.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg once daily, Duloxetine 60 mg twice daily, Duloxetine 20 mg once daily, and Placebo. Percentage of patients improved decreases as percent improvement in pain from baseline increases, with duloxetine groups generally showing higher improvement than placebo.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, showing curves for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis represents percent improvement in pain from baseline, while the y-axis represents the percentage of patients improved.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo, showing patient improvement trends across different pain improvement thresholds.*

FDA Label Image

Figure 6 (Duloxetine 07)

Line graph showing percent improvement in pain from baseline on the x-axis and percentage of patients with improved fibromyalgia symptoms on the y-axis. The graph compares Duloxetine delayed-release capsules at 20 mg, 60 mg, and 120 mg once daily doses against a placebo group.*

FDA Label Image

Figure 8 (Duloxetine 08)

Line graph showing the percentage of patients improved versus percent improvement in pain from baseline, comparing placebo and Duloxetine Delayed-Release 60 mg once daily. The graph plots patient improvement decreasing as pain improvement percentage declines, with data points and trend lines for both groups.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved over the percent improvement in pain from baseline between placebo and Duloxetine 60 mg once daily groups. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two data series: Placebo and Duloxetine Delayed-Release 60 mg/120 mg once daily, illustrating patient response in pain improvement over various improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.